Criteria to qualify for study: Drug used in study:
  • Must refuse or not be a candidate for intensive induction chemo.
  • Previously treated subjects should have evidence of persistent or recurrent AML
  • Newly Diagnosed AML or previously treated

HEMREF 48 - H3B-8800-101 H3 Biomedicine and Eisai

An Open-Label Multicenter Phase I trial to evaluate the Safety, Pharmacokynetics and Pharmacodynamic of Splicing Modulator H3B-800 for Subjects with AML.

Criteria to qualify for study: Drug used in study:
  • Newly Diagnosed

AML 35 CNTX-CX-01-2015 AML-1 Cantex

A Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed AML

Group 1 Idarubicin + Cytarabine
Group 2 Idarubicin + Cytarbine +lower dose CX-01
Group 3 Idarubicin + cytarbine + higher dose CX-01

Newly diagnosed untreated AML / Age 60 or above / ECOG 0 -2 / LVEF > 45% / CrCl >30mL/min / bili < 2.5 x ULN / prior treatment for AML / Excluded history of other active malignant diseases within 3 years prior / excluded pts receiving any form of anticoagulant therapy / excluded known bleeding disorder or coagulation abnormality

Criteria to qualify for study: Drug used in study:
  • Relapsed or Refractory

Hemref 43 TTI-621 Trillium

A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relpased of Refractory Hematologic Malignancies Phase 1a Escalation / Advanced lymphoma after failure of at least 2 prior regimens with at least 1 site of measurable disease (> 1.5 cm in long axis or > 1.0 cm in both long and short axis / ANC > 1.5 / PLT > 75 / HGB > 10 in absence of transfusion and growth factors for at least 28 days /ECOG 0,1 or 2 /

Criteria to qualify for study: Drug used in study:

Hemeref51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247"